B+
Bull case
0%
Probability
Target price
$245.00
+10.3% vs current
AXSM
Axsome TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+1Most likely
B
Base case
0%
Probability
Target price
$224.00
+0.8% vs current
B-
Bear case
0%
Probability
Target price
$185.00
-16.7% vs current
AI sentiment snapshot
Latest data as of 2026-05-04
Recent news sentiment (30D)
+0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+48.0
Score
AI commentary
This is a cautious positive T+1 earnings follow-up rather than a high-conviction thesis change. Primary-source evidence is strong because the 8-K and earnings press release are available, and the immediate market reaction was favorable, with AXSM up about 8.3% on May 4, 2026 after results. However, analyst target or estimate revisions are not yet available in the packet, so the memo should stay in monitoring mode until launch execution data and post-print sell-side digestion arrive.
RankAlpha Sentiment Codex - 2026-05-04
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-04eventAXS-12 NDA submission adds a regulatory checkpoint, but timing beyond filing remains undetailedHigh impact
The company disclosed that the NDA for AXS-12 in cataplexy associated with narcolepsy has been submitted to the FDA, which supports pipeline optionality, but the packet does not yet provide acceptance timing or a clearer review schedule, keeping this as a monitored rather than fully underwritten upside driver [#8-K-2026-05-04].
2026-05-04catalystQ1 print reinforced commercial momentum and drove a strong initial tape reactionMedium impact
Axsome reported 1Q26 net product revenue of $191.2 million, up 57% year over year, with AUVELITY net product revenue of $153.2 million and SUNOSI net product revenue of $33.9 million; the stock traded up about 8.3% on May 4, 2026 after the release, suggesting investors focused on revenue strength and the broadened commercial story [#8-K-2026-05-04].
2026-06-30catalystJune 2026 AUVELITY Alzheimer’s agitation launch is the next material commercialization checkpointHigh impact
Management said the commercial launch of AUVELITY in Alzheimer’s disease agitation is on track for June 2026 and that the recently announced sales-force expansion is substantially complete, creating a near-term test of whether the new indication can extend the product’s growth curve beyond core MDD demand [#8-K-2026-05-04].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-04 • Updated nightlySource: Internal modelMethodology